Gilead Sciences Inc

Latest stories

2d
Profit Confidential
GILD Stock: Is This Tiny Company the Next Gilead Sciences, Inc.?The disappointment is compounded when markets are making headway and making new
GILD Stock: Is This Tiny Company the Next Gilead Sciences, Inc.?
Profit Confidential / Posted 2 days ago
The disappointment is compounded when markets are making headway and making new all-time highs. This is my feeling toward Gilead Sciences, Inc. (NASDAQ:GILD) stock. The company is trading at $81.66 and is sitting at the lower end of a trading... Read more
3 related stories
5d
FOX News
Pfizer boosts cancer drug roster with $14B Medivation dealis just at the beginning of its growth cycle," he predicted. Reuters had repor
Pfizer boosts cancer drug roster with $14B Medivation deal
FOX News / Posted 5 days ago
is just at the beginning of its growth cycle," he predicted. Reuters had reported that Pfizer, Merck, Celgene Corp and Gilead Sciences Inc had submitted expressions of interest to buy Medivation. "Given the already very high price being... Read more
117 related stories
5d
Lowell Sun
Pfizer's big prize only costs $14Bdrugmaker Sanofi, whose aggressive and at one point hostile pursuit of Medivati
Pfizer's big prize only costs $14B
Lowell Sun / Posted 5 days ago
drugmaker Sanofi, whose aggressive and at one point hostile pursuit of Medivation helped open up the process to Pfizer, Gilead Sciences Inc. and others that were said to be involved. Pfizer will pay $81.50 a share in cash, the companies said in... Read more
117 related stories
5d
Times of Malta
Pfizer agrees to buy Medivation for $14bnputting itself up for sale. Reuters reported earlier this week that Pfizer, Sa
Pfizer agrees to buy Medivation for $14bn
Times of Malta / Posted 5 days ago
putting itself up for sale. Reuters reported earlier this week that Pfizer, Sanofi, Merck & Co Inc., Celgene Corp and Gilead Sciences Inc. had submitted expressions of interest to acquire Medivation. The strong acquisition interest in the San... Read more
117 related stories
6d
asianage
Pfizer's Medivation buy seen prescribing more biotech M&Arevenue. For the other companies that also bid for Medivation, including Sanof
Pfizer's Medivation buy seen prescribing more biotech M&A
asianage / Posted 6 days ago
revenue. For the other companies that also bid for Medivation, including Sanofi SA, Merck & Co Inc, Celgene Corp and Gilead Sciences Inc, such targets could serve as coveted consolation prizes. Major drug makers are vying for a foothold in... Read more
117 related stories
6d
Market Watch
Pfizer's Medivation deal isn't new for drug makera hefty sum at the time of the deal four years ago, may go down as one of the d
Pfizer's Medivation deal isn't new for drug maker
Market Watch / Posted 6 days ago
a hefty sum at the time of the deal four years ago, may go down as one of the drug industry's most lucrative transactions. Gilead Sciences Inc. obtained a promising but still unapproved hepatitis C drug. That compound was named Sovaldi upon its... Read more
117 related stories
6d
The Hindu
Pfizer to buy Medivation in $14-billion dealwatched," Leerink analysts wrote in a client note. Reuters had reported that Pf
Pfizer to buy Medivation in $14-billion deal
The Hindu / Posted 6 days ago
watched," Leerink analysts wrote in a client note. Reuters had reported that Pfizer, Merck & Co Inc, Celgene Corp and Gilead Sciences Inc had submitted expressions of interest to buy Medivation. “Given the already very high price being... Read more
117 related stories
6d
The Economic Times
Pfizer buys Medivation for $14 bn to boost cancer drug rostercould capture far greater sales if it is eventually approved for earlier use an
Pfizer buys Medivation for $14 bn to boost cancer drug roster
The Economic Times / Posted 6 days ago
could capture far greater sales if it is eventually approved for earlier use and becomes prescribed by urologists. and Gilead Sciences Inc had submitted expressions of interest to buy Medivation. "Given the already very high price being... Read more
117 related stories
6d
Providence Business News
Pfizer beats Sanofi with Medivation deal for $14Binitial offer, valued at about $9 billion, Medivation was able to bring in more
Pfizer beats Sanofi with Medivation deal for $14B
Providence Business News / Posted 6 days ago
initial offer, valued at about $9 billion, Medivation was able to bring in more potential suitors and drive up the bidding. Gilead Sciences Inc., Celgene Corp. and Amgen Inc. were among the other drugmakers reported to consider the deal. Sanofi... Read more
117 related stories
6d
The Globe and Mail
Pfizer to buy Medivation in $14-billion deal$81.50 per share in cash, a premium of 21.35 per cent to the stock’s Friday clo
Pfizer to buy Medivation in $14-billion deal
The Globe and Mail / Posted 6 days ago
$81.50 per share in cash, a premium of 21.35 per cent to the stock’s Friday close of $67.16. Reuters had reported that Pfizer, Sanofi, Merck & Co Inc , Celgene Corp and Gilead Sciences Inc had submitted expressions of interest to acquire Medivat... Read more
117 related stories
7d
The Globe and Mail
Pfizer nears deal to acquire Medivation for close to $14-billionin New York on Friday at $67.16. Reuters reported earlier this week that Pfize
Pfizer nears deal to acquire Medivation for close to $14-billion
The Globe and Mail / Posted 7 days ago
in New York on Friday at $67.16. Reuters reported earlier this week that Pfizer, Sanofi, Merck & Co Inc, Celgene Corp and Gilead Sciences Inc had submitted expressions of interest to acquire Medivation. The strong acquisition interest in the San... Read more
117 related stories
7d
Reuters
Pfizer nears deal to acquire Medivation for close to $14 billionat $67.16. Reuters reported earlier this week that Pfizer, Sanofi, Merck & Co
Pfizer nears deal to acquire Medivation for close to $14 billion
Reuters / Posted 7 days ago
at $67.16. Reuters reported earlier this week that Pfizer, Sanofi, Merck & Co Inc (MRK.N), Celgene Corp (CELG.O) and Gilead Sciences Inc (GILD.O) had submitted expressions of interest to acquire Medivation. The strong acquisition interest in... Read more
117 related stories
7d
Channel NewsAsia
Pfizer nears deal to acquire Medivation for close to US$14 billionNew York on Friday at US$67.16. Reuters reported earlier this week that Pfizer
Pfizer nears deal to acquire Medivation for close to US$14 billion
Channel NewsAsia / Posted 7 days ago
New York on Friday at US$67.16. Reuters reported earlier this week that Pfizer, Sanofi, Merck & Co Inc , Celgene Corp and Gilead Sciences Inc had submitted expressions of interest to acquire Medivation. The strong acquisition interest in the San... Read more
117 related stories
9d
Arkansas Democrat-Gazette
Anonymous panels decide Rx drug listsreact negatively toward that news," said Vishnu Lekraj, an analyst covering Exp
Anonymous panels decide Rx drug lists
Arkansas Democrat-Gazette / Posted 9 days ago
react negatively toward that news," said Vishnu Lekraj, an analyst covering Express Scripts for Morningstar. Shares of Gilead Sciences Inc. fell 14 percent on Dec. 22, 2014, when Express Scripts moved to exclude the drugmaker's new, high-cost... Read more
11d
Reuters
Merck enters race for cancer drugmaker Medivationlives, could mean billions of dollars in revenue to the companies that own them
Merck enters race for cancer drugmaker Medivation
Reuters / Posted 11 days ago
lives, could mean billions of dollars in revenue to the companies that own them. Sanofi SA, Pfizer Inc, Celgene Corp and Gilead Sciences Inc also put forward expressions of interest, the sources said. Medivation will have further conversations... Read more
25d
Business Standard India
Natco Pharma hits 52-week high on USFDA nod for generic Tamiflucompany said in a press release. Earlier in December, 2015, Natco Pharma and A
Natco Pharma hits 52-week high on USFDA nod for generic Tamiflu
Business Standard India / Posted 25 days ago
company said in a press release. Earlier in December, 2015, Natco Pharma and Alvogen settled a patent infringement with Gilead Sciences, Inc., Hoffmann-La Roche Inc., F. Hoffmann-La Roche Ltd. and Genentech, Inc. Under the terms of the... Read more
2 related stories
26d
Business Insurance
Express Scripts releases list of costly drugs it won't cover for 2017spokesman declined to say what magnitude or price rebates his company may have
Express Scripts releases list of costly drugs it won't cover for 2017
Business Insurance / Posted 26 days ago
spokesman declined to say what magnitude or price rebates his company may have won. Two costly drugs for hepatitis C from Gilead Sciences Inc., Epclusa and Harvoni, remain on the 2016 excluded medications list, he said. But he said their status... Read more
3 related stories
26d
FOX Business
Express Scripts Says Valeant, Lilly, Bristol Drugs to Lack CoverageWhitrap declined to say what magnitude or price rebates his company may have wo
Express Scripts Says Valeant, Lilly, Bristol Drugs to Lack Coverage
FOX Business / Posted 26 days ago
Whitrap declined to say what magnitude or price rebates his company may have won. Two costly drugs for hepatitis C from Gilead Sciences Inc, Epclusa and Harvoni, remain on the 2016 excluded medications list, Whitrap said. But he said their... Read more
3 related stories
26d
FOX Business
Express Scripts Says Valeant, Lilly, Bristol Drugs to Lack CoverageWhitrap declined to say what magnitude or price rebates his company may have wo
Express Scripts Says Valeant, Lilly, Bristol Drugs to Lack Coverage
FOX Business / Posted 26 days ago
Whitrap declined to say what magnitude or price rebates his company may have won. Two costly drugs for hepatitis C from Gilead Sciences Inc, Epclusa and Harvoni, remain on the 2016 excluded medications list, Whitrap said. But he said their... Read more
3 related stories
26d
The Register NorthJersey.com
Celgene accused of using charities ‘scheme’ to gain billionsinvestigators have begun examining whether some companies are working too close
Celgene accused of using charities ‘scheme’ to gain billions
The Register NorthJersey.com / Posted 26 days ago
investigators have begun examining whether some companies are working too closely with the charities. Earlier this year, Gilead Sciences Inc., Biogen Inc. and Jazz Pharmaceuticals Plc all disclosed receiving subpoenas from the U.S. Justice... Read more
30d
Investopedia
Top 5 Corporate Donors in Big Pharma (GILD, MRK)in 2015. Gilead Sciences Driven primarily by revenue gains resulting from its
Top 5 Corporate Donors in Big Pharma (GILD, MRK)
Investopedia / Posted 30 days ago
in 2015. Gilead Sciences Driven primarily by revenue gains resulting from its hepatitis C drugs Harvoni and Sovaldi, Gilead Sciences Inc. (NASDAQ: GILD) increased its cash donations in 2015 by 65% to $446.7 million, making the biotech firm... Read more
30d
The Register NorthJersey.com
Merck posts strong 2Q numbers, while building for long termin late January, posted sales of just $112 million. Merck is selling Zepatier a
Merck posts strong 2Q numbers, while building for long term
The Register NorthJersey.com / Posted 30 days ago
in late January, posted sales of just $112 million. Merck is selling Zepatier at a slight discount to entrenched leader Gilead Sciences Inc.'s Harvoni and Sovaldi, which are raking in billions each quarter. Keytruda had sales of $314 million,... Read more
4 related stories
30d
Philly.com
Merck posts strong 2Q numbers, while building for long termin late January, posted sales of just $112 million. Merck is selling Zepatier a
Merck posts strong 2Q numbers, while building for long term
Philly.com / Posted 30 days ago
in late January, posted sales of just $112 million. Merck is selling Zepatier at a slight discount to entrenched leader Gilead Sciences Inc.'s Harvoni and Sovaldi, which are raking in billions each quarter. Keytruda had sales of $314 million,... Read more
4 related stories

People in this news